Clozapine-aripiprazole association in a 7-year-old girl with schizophrenia: Clinical efficacy and successful management of neutropenia with lithium

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 5, 2009, Pages 595-598

  Gagliano, Antonella ^a   Masi, Gabriele ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; LITHIUM; RISPERIDONE; TAMOXIFEN; VALPROIC ACID;

APPETITE; BODY MASS; CASE REPORT; CHILD; CHILD BEHAVIOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; ELECTROENCEPHALOGRAM; FEMALE; GENOME ANALYSIS; HOSPITALIZATION; HUMAN; LABORATORY TEST; LETTER; NEUTROPHIL COUNT; SCHIZOPHRENIA; SCHOOL CHILD; SPEECH; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CHILD; CLOZAPINE; FEMALE; HUMANS; LITHIUM CARBONATE; NEUTROPENIA; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 70449113591     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0012     Document Type: Letter

References (23)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington (DC): American Psychiatric Association.
2. Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, Kim YS: Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69:720-731, 2008.
3. Englisch S, Zink M: Combined antipsychotic treatment involving clozapine and aripiprazole. Progr Neuropsychopharmacol Biol Psychiatry 32:1386-1392, 2008.
4. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH: A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432-1441, 2008a.
5. Findling RL, Short EJ, Leskovec T, Townsend LD, Demeter CA, Mcnamara CK, Stansbrey RJ: Aripiprazole in children with attention- deficit=hyperactivity disorder. J Child Adolesc Psychopharmacol 18, 347-354, 2008b.
6. Gerbino-Rosen G, Roofeh D, Thomkins A, Feryo D, Nusser L, Kranzler H, Napolitano B, Fredrickson A, Rhinewine J, Kumra S: Hematological adverse events in clozapine-treated children and adolescents. J Child Adolesc Psychopharmacol 15:857, 2005.
7. Hollis C: Adult outcomes of child- and adolescent-onset schizophrenia: Diagnostic stability and predictive validity. Am J Psychiatry 157:1652-1659, 2000.
8. Karaguzel G, Ackurin S, Yakut S, Bircan I: Reported on a case of 22q11 deletion syndrome, associated with psychiatric disorder, precocious puberty and hypoparathyroidism. J Pediatr Endocrinol Metabolism 19:761-764, 2006.
9. Kern RF, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, Ali M, Marcus R: The neurocognitive effect of aripiprazole: An open label comparison with olanzapine. Psychopharmacology 187:312-320, 2006.
10. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL: Childhood onset schizophrenia.Adouble-blind clozapinehaloperidol comparison. Arch Gen Psychiatry 55:90-92, 1996.
11. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, Charles Schulz S: Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophrenia Bull 34:60-71, 2008a.
12. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Kafantaris V, Correll CU, Kane JM: Clozapine and ''high dose'' olanzapine in refractory early-onset schizophrenia: A 12 week randomized and double-blind comparison. Biol Psychiatry 63: 524-529, 2008b.
13. Masi G, Mucci M, Pari C: Children with schizophrenia: Clinical picture and pharmacological treatment. CNS Drugs 20:841-866, 2006.
14. Oyffe I, Lerner A, Isaacs G, Harel Y, Sigal M: Clomiphene-induced psychosis. Am J Psychiatry 154:1169-1170, 1997.
15. Pope HG, Cole JO, Choras PT, Fulwiler CE: Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 174:493-495, 1986.
16. Prasad SE, Howley S, Murphy KC: Psychiatric disorders in people with 22q11.2 deletion syndrome: A population-based prevalence study in Ireland. J Intellect Disabil Res 52:816, 2008.
17. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Grochman P, Tossel JW, Lenane M, Rapoport JL: Childhood-onset schizophrenia: A double-blind, randomized, clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721-730, 2006.
18. Shin L, Bregman H, Frazier J, Noves N: An overview of obesity in children with psychiatric disorders taking atypical antipsychotics. Harv Rev Psychiatry 16:69-79, 2008.
19. Sporn A, Gogtay N, Ortiz-Aguayo R, Alfaro C, Tossell J, Lenane M, Gochman P, Rapoport JL: Clozapine-induced neutropenia in children: Management with lithium carbonate. J Child Adolesc Psychopharmacol 13:401-404, 2003.
20. Ty EB, Rothner AD: Neuroleptic malignant syndrome in children and adolescents. J Child Neurol 16:157-163, 2001.
21. Werry JS, McClellan JM: Predicting outcome in child and adolescent (early onset) schizophrenia and bipolar disorder. J Am Acad Child Adolesc Psychiatry 31:147-150, 1992.
22. Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF: Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 65:255-263, 2008.
23. Zarate CA Jr, Singh JB, Carlson PJ, Quiroz J, Jolkowsky L, Luckenbaugh DA, Manji HK: Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study. Bipolar Disord 9:561-570, 2007.